Literature DB >> 29081013

Emerging Technologies in Flow Diverters and Stents for Cerebrovascular Diseases.

Michael Karsy1, Jian Guan1, Andrea A Brock1, Anubhav Amin2, Min S Park3,4.   

Abstract

PURPOSE OF REVIEW: Stents and flow diverters have revolutionized the treatment of cerebrovascular disease. Guglielmi coils, flexible microcatheters, and first-generation intracranial stents, such as Neuroform (Stryker Neurovascular) and Enterprise stents (Codman/DePuy-Synthes), have paved the way for the development of the Pipeline Embolization Device (PED) (ev3/Covidien/Medtronic) and other endovascular approaches. RECENT
FINDINGS: This review discusses the historical development of flow diverter technologies from the PED to similar devices, such as the Surpass stent (Stryker Neurovascular), the Flow-Redirection Endoluminal Device (FRED; MicroVention, Inc.), the SILK stent (Balt Extrusion), and the p64 Flow Modulation Device (Phenox). In addition, the potential use of drug-eluting stents and various bioresorbable scaffolds (e.g., poly-L-lactic acid, magnesium), new developments in stent material (e.g., thin-film nitinol), design (e.g., biocompatible polymers, embedded microcircuitry, flow models), and potential applications for flow diverters will be considered. Endovascular treatment of cerebrovascular disease is rapidly advancing via continued development of new technology.

Entities:  

Keywords:  Bioresorbable; Drug-eluting stents; Flow diverter; Intracranial stent

Mesh:

Year:  2017        PMID: 29081013     DOI: 10.1007/s11910-017-0805-3

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  49 in total

Review 1.  The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease.

Authors:  Kate McKeage; David Murdoch; Karen L Goa
Journal:  Am J Cardiovasc Drugs       Date:  2003       Impact factor: 3.571

2.  Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies.

Authors:  Ajay J Kirtane; Anuj Gupta; Srinivas Iyengar; Jeffrey W Moses; Martin B Leon; Robert Applegate; Bruce Brodie; Edward Hannan; Kishore Harjai; Lisette Okkels Jensen; Seung-Jung Park; Raphael Perry; Michael Racz; Francesco Saia; Jack V Tu; Ron Waksman; Alexandra J Lansky; Roxana Mehran; Gregg W Stone
Journal:  Circulation       Date:  2009-06-15       Impact factor: 29.690

3.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

Authors:  Peter Wenaweser; Joost Daemen; Marcel Zwahlen; Ron van Domburg; Peter Jüni; Sophia Vaina; Gerrit Hellige; Keiichi Tsuchida; Cyrill Morger; Eric Boersma; Neville Kukreja; Bernhard Meier; Patrick W Serruys; Stephan Windecker
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

Review 4.  Flow diversion for intracranial aneurysms: a review.

Authors:  Pietro I D'Urso; Giuseppe Lanzino; Harry J Cloft; David F Kallmes
Journal:  Stroke       Date:  2011-07-07       Impact factor: 7.914

5.  Long-Term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents.

Authors:  Soji Nishio; Kunihiko Kosuga; Keiji Igaki; Masaharu Okada; Eisho Kyo; Takafumi Tsuji; Eiji Takeuchi; Yasutaka Inuzuka; Shinsaku Takeda; Tatsuhiko Hata; Yuzo Takeuchi; Yoshitaka Kawada; Takeshi Harita; Junya Seki; Shunji Akamatsu; Shinichi Hasegawa; Nico Bruining; Salvatore Brugaletta; Sebastiaan de Winter; Takashi Muramatsu; Yoshinobu Onuma; Patrick W Serruys; Shigeru Ikeguchi
Journal:  Circulation       Date:  2012-04-16       Impact factor: 29.690

6.  Angiographic analysis for phantom simulations of endovascular aneurysm treatments with a new fully retrievable asymmetric flow diverter.

Authors:  Aradhana Yoganand; Rachel P Wood; Carlos Jimenez; Adnan Siddiqui; Kenneth Snyder; S V Setlur Nagesh; D R Bednarek; S Rudin; Robert Baier; Ciprian N Ionita
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2015-03-17

7.  Treatment of 14 intracranial aneurysms with the FRED system.

Authors:  Orlando Diaz; Taylor L Gist; Ginna Manjarez; Fernando Orozco; Rafael Almeida
Journal:  J Neurointerv Surg       Date:  2013-09-23       Impact factor: 5.836

8.  New stent surface materials: the impact of polymer-dependent interactions of human endothelial cells, smooth muscle cells, and platelets.

Authors:  Raila Busch; Anne Strohbach; Stefanie Rethfeldt; Simon Walz; Mathias Busch; Svea Petersen; Stephan Felix; Katrin Sternberg
Journal:  Acta Biomater       Date:  2013-10-19       Impact factor: 8.947

9.  Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials.

Authors:  Shuzou Tanimoto; Patrick W Serruys; Leif Thuesen; Dariusz Dudek; Bernard de Bruyne; Bernard Chevalier; John A Ormiston
Journal:  Catheter Cardiovasc Interv       Date:  2007-10-01       Impact factor: 2.692

10.  A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.

Authors:  Stefan Verheye; John A Ormiston; James Stewart; Mark Webster; Elias Sanidas; Ricardo Costa; J Ribamar Costa; Daniel Chamie; Andrea S Abizaid; Ibraim Pinto; Lynn Morrison; Sara Toyloy; Vinayak Bhat; John Yan; Alexandre Abizaid
Journal:  JACC Cardiovasc Interv       Date:  2013-10-16       Impact factor: 11.195

View more
  2 in total

1.  Delayed rupture of intracranial aneurysms after placement of intra-luminal flow diverter.

Authors:  Kun Hou; Guichen Li; Xianli Lv; Baofeng Xu; Kan Xu; Jinlu Yu
Journal:  Neuroradiol J       Date:  2020-08-27

2.  The Evolution of Flow-Diverting Stents for Cerebral Aneurysms; Historical Review, Modern Application, Complications, and Future Direction.

Authors:  Dong-Seong Shin; Christopher P Carroll; Mohammed Elghareeb; Brian L Hoh; Bum-Tae Kim
Journal:  J Korean Neurosurg Soc       Date:  2020-02-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.